T1	Lab_value_phrase 343 405	she then initiated standard daily dosing of erlotinib (150 mg)
T2	Lab_value 398 404	150 mg
T3	Diagnostic_procedure 362 370	standard
T4	Lab_value_phrase 1287 1390	She initiated empiric temozolomide plus standard dose erlotinib (150 mg daily) for presumed CNS disease
T5	Lab_value 1352 1358	150 mg
T6	Diagnostic_procedure 1309 1321	temozolomide
T7	Lab_value_phrase 2487 2556	Standard dose erlotinib (150 mg daily) achieves 3000 nM in plasma [7]
T8	Lab_value 2512 2518	150 mg
T9	Diagnostic_procedure 2496 2500	dose
T10	Lab_value_phrase 2853 2956	An analogous increase of the daily erlotinib dose above 150â€“200 mg daily induces unacceptable toxicity.
T11	Lab_value 2913 2919	200 mg
T12	Diagnostic_procedure 2898 2902	dose
T13	Lab_value_phrase 2966 3024	weekly high-dose erlotinib up to 2000 mg is tolerable [4].
T14	Lab_value 2999 3006	2000 mg
T15	Diagnostic_procedure 2966 2972	weekly
T16	Lab_value_phrase 3025 3242	Pharmacokinetic analysis of CSF from another patient with NSCLC LM (not shown) treated with 1500 mg erlotinib weekly demonstrated a peak plasma concentration of 11,300 nM with a concurrent CSF concentration of 130 nM.
T17	Lab_value 3117 3124	1500 mg
T18	Diagnostic_procedure 3193 3195	nM
T19	Lab_value_phrase 3353 3508	Therefore, to increase CSF penetrance over standard daily erlotinib dosing in this patient, we initiated high-dose weekly erlotinib at 1000 mg then 1200 mg
T20	Lab_value 3488 3495	1000 mg
T21	Diagnostic_procedure 3376 3379	CSF
T22	Lab_value_phrase 3894 3958	after which she resumed treatment with 1500 mg weekly erlotinib.
T23	Lab_value 3933 3940	1500 mg
T24	Diagnostic_procedure 3918 3927	treatment
T25	Lab_value_phrase 4046 4109	erlotinib was continued but changed to low dose (100 mg) daily.
T26	Lab_value 4095 4101	100 mg
T27	Diagnostic_procedure 4089 4093	dose
